Abstract

You have accessJournal of UrologyCME1 May 2022PD51-04 MEDIUM TO LONG TERM HEALTH-RELATED QUALITY OF LIFE AND TREATMENT-RELATED SIDE-EFFECTS IN PATIENTS TREATED WITH A SINGLE DOSE OF ADJUVANT CARBOPLATIN FOR HIGH-RISK SEMINOMA – RESULTS FROM A PILOT STUDY Walter Cazzaniga, Adam Pearce, Chandran Tanabalan, Prabhakar Rajan, Netty Kinsella, Alison Reid, Robert Huddart, and David Nicol Walter CazzanigaWalter Cazzaniga More articles by this author , Adam PearceAdam Pearce More articles by this author , Chandran TanabalanChandran Tanabalan More articles by this author , Prabhakar RajanPrabhakar Rajan More articles by this author , Netty KinsellaNetty Kinsella More articles by this author , Alison ReidAlison Reid More articles by this author , Robert HuddartRobert Huddart More articles by this author , and David NicolDavid Nicol More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002622.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Medium and long-term side effects of a single dose of adjuvant carboplatin AUC 7 for high-risk stage 1 seminoma are thought to be rare. Persisting symptoms and quality of life impact of treatment for patients have yet to be defined. Here, we study the medium-long term Health-related quality of life (HRQoL) and treatment-related symptoms of testicular cancer (TC) patients treated with 1xCarboplatin following orchidectomy for high-risk stage 1 seminoma. METHODS: Data obtained from 32 patients divided into 2 treatment groups were analysed (1: Orchidectomy alone – reference group; 2: Orchidectomy + 1xCarboplatin AUC 7). HRQoL was assessed using the validated EQ-5D-5L metric together with a TC specific questionnaire, the EORTC TC26, that has been previously used to study post-treatment side effect severity. To evaluate the medium to long term side effects of treatment all patients included in the study had completed TC treatment 12 to 24 months prior to the administration of the questionnaire. RESULTS: Using the EQ-5D-5L metrics, patients treated with 1xCarboplatin exhibited low and comparable proportions of impairment in the mobility, self-care, and usual activities domains, as compared to the orchidectomy group (0% Vs 0%; 0% Vs 0%; 0% Vs 5.6%; respectively). In contrast, the 1xCarboplatin group, were more prone to report pain or discomfort problems (30.8% Vs 21%).Patients treated with orchidectomy alone however reported twice the rate of anxiety/depression issues compared to 1xCarboplatin group (58% Vs 30%).With the EORTC TC26 questions, both 1xCarboplatin and orchidectomy alone demonstrated identical medium to long term side effects profiles. Patients who received adjuvant treatment reported almost half the rate of uncertainty concerning their future (39% Vs 69%) and identical self-perceived Health status (81.53% Vs 81.15%), compared to those who had orchiectomy alone. CONCLUSIONS: The addition of 1xCarboplatin for high-risk stage1 seminoma does not increase the medium to long term side effects compared to patients with low-risk disease who underwent orchidectomy alone. Furthermore, adjuvant carboplatin is associated with higher levels of patient perception of care and also reduces anxiety and uncertainty about possible cancer recurrence. Further studies are needed to verify these findings as this information may be a necessary addition to the information provided to patients in contemplating their treatment decision for high-risk stage1 seminoma. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e843 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Walter Cazzaniga More articles by this author Adam Pearce More articles by this author Chandran Tanabalan More articles by this author Prabhakar Rajan More articles by this author Netty Kinsella More articles by this author Alison Reid More articles by this author Robert Huddart More articles by this author David Nicol More articles by this author Expand All Advertisement PDF DownloadLoading ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.